Medicines Optimisation Research Group, School of Applied Sciences, University of Brighton, Brighton, UK.
Pharmacy Department, University Hospitals Sussex NHS Foundation Trust, Brighton, UK.
Sci Rep. 2022 May 25;12(1):8833. doi: 10.1038/s41598-022-12591-w.
The Coronavirus Disease 2019 (COVID)-19 pandemic has placed unprecedented pressures on societies around the world. Successful vaccines, developed against the spike protein of the Severe Acute Respiratory Syndrome Virus 2 (SARS-CoV-2) virus, offer hope that new hospitalisations and new deaths will subside. However, vaccination takes place in a dynamic environment. For example, new variants of the disease may occur where the effectiveness of a vaccine lies below that of the original target of the vaccine, while changes in the behaviour of a population are accompanied by a changed basic reproduction number. Here, we aim to understand how changes in values of basic parameters affect the benefits of vaccination at the direct level, of the individuals vaccinated, and at the indirect level, of the wider, unvaccinated community. We work within the framework of a Susceptible-Infected-Recovered model, and produce a metric for the benefits of vaccination, at both direct and indirect levels, in terms of the number of avoided deaths. Taking into account the initial prevalence of a SARS-CoV-2 infection, the mortality rate of the disease, the basic reproduction number, the vaccination rate, and the effectiveness of a vaccine, we explore how these basic parameters affect the benefits of vaccination. We find a range of situations where indirect benefits of vaccination outweigh direct benefits. This especially occurs at lower rates of vaccination (20% - [Formula: see text]) and intermediate values of the basic reproduction number (1-1.5). The indirect benefits can be substantial, in some cases being more than 400% of the direct benefits. For an initial prevalence of SARS-CoV-2 infection of 2%, a basic reproduction number of 1.2, a mortality rate of 2%, and a vaccine effectiveness of 95%, our findings show, for a population of 500,000 people, where 100,000 susceptible individuals are vaccinated, that approximately 2200 deaths are avoided. However, approximately 600 of these deaths are avoided amongst vaccinated individuals, while approximately 1600 deaths are avoided in the wider, unvaccinated community.
2019 年冠状病毒病(COVID-19)大流行给全世界的社会带来了前所未有的压力。针对严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)病毒的刺突蛋白开发的成功疫苗带来了新的希望,即新的住院和新的死亡人数将减少。然而,疫苗接种是在一个动态的环境中进行的。例如,可能会出现疾病的新变体,疫苗的有效性低于疫苗的原始目标,而人口行为的变化伴随着基本繁殖数的变化。在这里,我们旨在了解基本参数值的变化如何直接影响个体接种疫苗的益处,以及间接影响未接种疫苗的更广泛人群的益处。我们在易感-感染-恢复模型的框架内工作,并以避免死亡人数为指标,来衡量直接和间接水平上接种疫苗的好处。考虑到 SARS-CoV-2 感染的初始流行率、疾病的死亡率、基本繁殖数、疫苗接种率和疫苗的有效性,我们探讨了这些基本参数如何影响疫苗接种的好处。我们发现了一系列情况下,间接接种疫苗的好处超过了直接接种疫苗的好处。这种情况尤其发生在较低的接种率(20%-[公式:见正文])和中等基本繁殖数(1-1.5)。在某些情况下,间接效益可能非常大,超过直接效益的 400%。对于 SARS-CoV-2 感染的初始流行率为 2%、基本繁殖数为 1.2、死亡率为 2%和疫苗有效性为 95%的情况,我们的研究结果表明,对于一个拥有 50 万人口的人群,如果有 10 万人易感染,其中 10 万人接种疫苗,大约可以避免 2200 人死亡。然而,大约有 600 人是在接种疫苗的人群中避免死亡,而大约有 1600 人是在未接种疫苗的更广泛人群中避免死亡。